# Oliver Reuss

> Oliver Reuss is a Series A investor at Boehringer Ingelheim Venture Fund backing Medical. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Boehringer Ingelheim Venture Fund](https://shizune.co/investors/profile/boehringer-ingelheim-venture-fund)
- Total investments: 3
- Last investment: Mar 2025
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/oliver-reuss-45a56317/

Oliver Reuss is a Series A investor at Boehringer Ingelheim Venture Fund focused on Medical and Software. Oliver Reuss serves as an Executive Director and Investment Manager at Boehringer Ingelheim Venture Fund.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 33% |
| Software | 1 | 33% |
| Wellness | 1 | 33% |
| Therapeutics | 1 | 33% |
| Biotechnology | 1 | 33% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 33% |
| Series B | 1 | 33% |
| Series C | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Germany | 1 | 33% |
| United Kingdom | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Brainomix | Since launching as a spin-out from the University of Oxford in 2010, Brainomix has developed award-winning, AI-powered imaging biomarkers, assisting physicians across the world to make better life-saving decisions. Brainomix seminal product, e-Stroke is a collection of tools that use state-of-the-art AI algorithms to support doctors by providingreal-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients, allowing more patients to get the right treatment, in the right place, at the right time. | $18.2M | Series C | Mar 18, 2025 |  |
| Brainomix | Since launching as a spin-out from the University of Oxford in 2010, Brainomix has developed award-winning, AI-powered imaging biomarkers, assisting physicians across the world to make better life-saving decisions. Brainomix seminal product, e-Stroke is a collection of tools that use state-of-the-art AI algorithms to support doctors by providingreal-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients, allowing more patients to get the right treatment, in the right place, at the right time. | $21.3M | Series B | Dec 16, 2021 |  |
| Perfood | Perfood is a digital therapeutic startup that identifies what actions need to take on a personalized level, to prevent or fight diseases. Using sensors, lab results, and holistic analyses, they derive therapeutic angles and deliver them in a slick, easy-to-use way, making them accessible for all patients. They call this approach digitaltherapeutics. A digital solution that is just as effective as a drug. But without side effects. | $6M | Series A | Nov 30, 2020 |  |

3 of 3 investments shown.

## Co-investors
- [Parkwalk Advisors](https://shizune.co/investors/profile/parkwalk-advisors) — VC Fund, 3 deals together
- [Hostplus](https://shizune.co/investors/profile/hostplus) — VC Fund, 1 deal together
- [LifeSci Capital](https://shizune.co/investors/profile/lifesci-capital) — VC Fund, 1 deal together
- [Oxford University Innovation](https://shizune.co/investors/profile/oxford-university-innovation) — VC Fund, 1 deal together
- [Tencent](https://shizune.co/investors/profile/tencent) — VC Fund, 1 deal together
- [UV-Cap](https://shizune.co/investors/profile/uv-cap) — VC Fund, 1 deal together

## About Boehringer Ingelheim Venture Fund

VC Fund · Ingelheim Am Rhein, Germany

Boehringer Ingelheim Venture Fund intends to invest in groundbreaking therapeutic approaches and technologies.

4 contacts available at Boehringer Ingelheim Venture Fund.

| Name | Title | Profile |
| --- | --- | --- |
| Debbie Lin | Executive Director | https://shizune.co/investors/profile/debbie-w-lin |
| Knut Elbers | Project Manager | https://shizune.co/investors/profile/knut-elbers |
| Martin Heidecker | Managing Director | https://shizune.co/investors/profile/martin-heidecker |
| Oliver Reuss | Executive Director and Investment Manager | https://shizune.co/investors/profile/oliver-reuss |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Oliver Reuss invest in?

Oliver Reuss invests primarily in Medical, Software and Wellness startups, most often at Series A and Series B stage. Most of the 3 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Oliver Reuss last invest?

The most recent investment recorded for Oliver Reuss closed in Mar 2025. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co